Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, ERP, FVT

Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights


COPENHAGEN, Denmark, Nov. 14, 2018 /PRNewswire/ --

Highlights

(PRNewsfoto/Veloxis Pharmaceuticals)

In connection with the financial report, Veloxis's CEO, Craig Collard said:

"We are very excited about the wide-spread use of Envarsus among transplant centers.  Veloxis has strong momentum as we move into the final quarter of 2018." 

Outlook for 2018

Veloxis maintains its 2018 outlook of revenues to be in the range of USD 36 ? 42 million, and operating loss before accounting for stock compensation in the range of USD 2 ? 6 million. 

Conference Call

A conference call will be held tomorrow, 15 November 2018 at 4:00 PM CET (Denmark); 10:00 AM EST (New York).

To access the conference call, please dial one of the following numbers:

Confirmation Code:  3860316

U.S.: +1 929 477 0324
UK:  +44 (0) 330 336 9411
DK: +45 35 15 81 21

Following the conference call, a recording will be available on the Company's website: http://www.veloxis.com.

About Envarsus XR

Envarsus (tacrolimus prolonged-release tablets) has received marketing authorization in the EU for prophylaxis of organ rejection in kidney and liver transplant recipients and in the U.S., branded as Envarsus XR (tacrolimus extended-release tablets) for prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate release formulations in combination with other immunosuppressants.  Envarsus XR has received orphan drug designation in the U.S.  Veloxis launched Envarsus XR in the U.S. through its own sales force and in the EU through its partnership with Chiesi Farmaceutici S.p.A. 

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, U.S.A.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties.  Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO. 

For further information, please visit: www.veloxis.com.

SOURCE Veloxis Pharmaceuticals


These press releases may also interest you

at 10:30
Unifi Aviation is making a pledge to employ 500 refugees over the next three years, a commitment the company made at the second annual TENT U.S. Business Summit on Refugees hosted by Pfizer at its global headquarters in New York City on March 26....

at 10:15
Today, Investopedia announced the winners of its 2024 Best Online Broker Awards, featuring 14 categories highlighting winners whose products and services helped investors navigate rising but volatile markets, a crypto resurgence, and new assets like...

at 10:12
NerdsToGo®, a leading information technology (IT) solutions and technology repair services franchise for both business and home, announced today plans for its strategic expansion throughout the greater Chicago area with 20 new territories available...

at 10:10
The group division of Ameritas proudly announces its 17th consecutive certification as a BenchmarkPortal Center of Excellence, solidifying its position as a leader in customer service and support excellence. This prestigious recognition for 2023...

at 10:00
Frost & Sullivan recently researched the customer experience outsourcing services industry and, based on its findings, recognizes AeC with the 2023 Company of the Year Award. AeC is connecting technology with outstanding customer service to increase...

at 10:00
Seniors Helping Seniors® in-home care services, a franchisor with over 125 franchise partners and more than 200 territories nationwide, has grown rapidly in recent years by building a workforce of talented caregivers who create meaningful...



News published on and distributed by: